Cbf Bueno1, E B Trarbach2, M D Bronstein2, A Glezer2. 1. Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clínicas & Laboratory of Cellular and Molecular Endocrinology LIM-25, University of São Paulo Medical School, São Paulo, Brazil. cbformiga@gmail.com. 2. Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clínicas & Laboratory of Cellular and Molecular Endocrinology LIM-25, University of São Paulo Medical School, São Paulo, Brazil.
Abstract
BACKGROUND: About 80% of prolactinomas respond to dopamine agonists (DA) with hormonal normalization and tumor shrinkage. Mechanisms of DA resistance include reduction of dopamine receptor subtype 2 (DRD2) expression, short and long isoform ratio and post-receptor mechanisms. It was suggested that polymorphisms in the gene encoding dopamine receptor subtype 2 gene (DRD2) could be associated with variable effectiveness of cabergoline (CAB). OBJECTIVE: To assess the influence of DRD2 polymorphisms in responsiveness of CAB treatment in patients with prolactinoma. STUDY DESIGN AND PATIENTS: Cross-sectional retrospective case-control study analyzing the frequency of five DRD2 polymorphisms in 148 patients with prolactinoma and 349 healthy subjects. The association of genetic variants and clinical characteristics with CAB responsiveness was performed in 118 patients (mean age at diagnosis 29 years; range 11-61 years) with hormonal evaluation. Patients with prolactin (PRL) normalization were considered as responders. RESULTS: No association in genotypes and allele proportions was found comparing patients and controls. On pharmacogenetic study, 118 patients on CAB were included and 20% were non-responders. No association was found between clinical characteristics (gender, age, PRL level and tumor size at diagnosis) and polymorphisms of DRD2 with CAB responsiveness. Otherwise, there was association between polymorphisms rs1076560 (allele A) and rs1800497 (allele T) and the presence of macroadenomas. CONCLUSION: No correlation was found between DRD2 polymorphisms and CAB responsiveness in patients with prolactinoma. More data are necessary in order to assess the influence of DRD2 genotyping on DA treatment response.
BACKGROUND: About 80% of prolactinomas respond to dopamine agonists (DA) with hormonal normalization and tumor shrinkage. Mechanisms of DA resistance include reduction of dopamine receptor subtype 2 (DRD2) expression, short and long isoform ratio and post-receptor mechanisms. It was suggested that polymorphisms in the gene encoding dopamine receptor subtype 2 gene (DRD2) could be associated with variable effectiveness of cabergoline (CAB). OBJECTIVE: To assess the influence of DRD2 polymorphisms in responsiveness of CAB treatment in patients with prolactinoma. STUDY DESIGN AND PATIENTS: Cross-sectional retrospective case-control study analyzing the frequency of five DRD2 polymorphisms in 148 patients with prolactinoma and 349 healthy subjects. The association of genetic variants and clinical characteristics with CAB responsiveness was performed in 118 patients (mean age at diagnosis 29 years; range 11-61 years) with hormonal evaluation. Patients with prolactin (PRL) normalization were considered as responders. RESULTS: No association in genotypes and allele proportions was found comparing patients and controls. On pharmacogenetic study, 118 patients on CAB were included and 20% were non-responders. No association was found between clinical characteristics (gender, age, PRL level and tumor size at diagnosis) and polymorphisms of DRD2 with CAB responsiveness. Otherwise, there was association between polymorphisms rs1076560 (allele A) and rs1800497 (allele T) and the presence of macroadenomas. CONCLUSION: No correlation was found between DRD2 polymorphisms and CAB responsiveness in patients with prolactinoma. More data are necessary in order to assess the influence of DRD2 genotyping on DA treatment response.
Authors: Ronald Rodrigues de Moura; Antonio Victor Campos Coelho; Valdir de Queiroz Balbino; Sergio Crovella; Lucas André Cavalcanti Brandão Journal: Am J Hum Biol Date: 2015-03-26 Impact factor: 1.937
Authors: E G Jönsson; M M Nöthen; F Grünhage; L Farde; Y Nakashima; P Propping; G C Sedvall Journal: Mol Psychiatry Date: 1999-05 Impact factor: 15.992
Authors: A Colao; A Di Sarno; M L Landi; S Cirillo; F Sarnacchiaro; G Facciolli; R Pivonello; M Cataldi; B Merola; L Annunziato; G Lombardi Journal: J Clin Endocrinol Metab Date: 1997-11 Impact factor: 5.958
Authors: Jubao Duan; Mark S Wainwright; Josep M Comeron; Naruya Saitou; Alan R Sanders; Joel Gelernter; Pablo V Gejman Journal: Hum Mol Genet Date: 2003-02-01 Impact factor: 6.150
Authors: Sérgio D J Pena; Giuliano Di Pietro; Mateus Fuchshuber-Moraes; Julia Pasqualini Genro; Mara H Hutz; Fernanda de Souza Gomes Kehdy; Fabiana Kohlrausch; Luiz Alexandre Viana Magno; Raquel Carvalho Montenegro; Manoel Odorico Moraes; Maria Elisabete Amaral de Moraes; Milene Raiol de Moraes; Elida B Ojopi; Jamila A Perini; Clarice Racciopi; Andrea Kely Campos Ribeiro-Dos-Santos; Fabrício Rios-Santos; Marco A Romano-Silva; Vinicius A Sortica; Guilherme Suarez-Kurtz Journal: PLoS One Date: 2011-02-16 Impact factor: 3.240